1
0
mirror of https://github.com/msberends/AMR.git synced 2026-07-12 15:10:57 +02:00

(v3.0.1.9085) website

This commit is contained in:
2026-07-09 21:05:33 +02:00
parent 9237bfbc19
commit c4069da61f
13 changed files with 68 additions and 57 deletions

View File

@@ -27,12 +27,9 @@
<div style="display: flex; font-size: 0.8em;">
<p style="text-align:left; width: 50%;">
<small><a href="https://amr-for-r.org/">amr-for-r.org</a></small>
</p>
<p style="text-align:right; width: 50%;">
<small><a href="https://doi.org/10.18637/jss.v104.i03" target="_blank">doi.org/10.18637/jss.v104.i03</a></small>
</p>
@@ -49,8 +46,10 @@ R package with [zero
dependencies](https://en.wikipedia.org/wiki/Dependency_hell) to simplify
the analysis and prediction of Antimicrobial Resistance (AMR) and to
work with microbial and antimicrobial data and properties, by using
evidence-based methods. **Our aim is to provide a standard** for clean
and reproducible AMR data analysis, that can therefore empower
evidence-based methods.
**Our aim has always been to provide a standard** for clean and
reproducible AMR data analysis, that can therefore empower
epidemiological analyses to continuously enable surveillance and
treatment evaluation in any setting. We are a team of [many different
researchers](./authors.html) from around the globe to make this a
@@ -60,7 +59,7 @@ times](https://scholar.google.com/citations?view_op=view_citation&hl=en&citation
in scientific research.
After installing this package, R knows [**~97 000 distinct microbial
species**](./reference/microorganisms.html) (updated May 2026) and all
species**](./reference/microorganisms.html) (updated mei 2026) and all
[**~620 antimicrobial and antiviral
drugs**](./reference/antimicrobials.html) by name and code (including
ATC, EARS-Net, ASIARS-Net, PubChem, LOINC and SNOMED CT), and knows all
@@ -171,11 +170,13 @@ example_isolates %>%
#> Using column mo as input for `mo_fullname()`
#> Using column mo as input for `mo_is_gram_negative()`
#> Using column mo as input for `mo_is_intrinsic_resistant()`
#> Determining intrinsic resistance based on 'EUCAST Expected Resistant Phenotypes' v1.2 (2023).
#> This note will be shown once per session.
#> For `aminoglycosides()` using columns GEN (gentamicin), TOB (tobramycin), AMK (amikacin), and KAN
#> (kanamycin)
#> For `carbapenems()` using columns IPM (imipenem) and MEM (meropenem)
#> Determining intrinsic resistance based on 'EUCAST Expected
#> Resistant Phenotypes' v1.2 (2023). This note will be shown
#> once per session.
#> For `aminoglycosides()` using columns GEN (gentamicin), TOB
#> (tobramycin), AMK (amikacin), and KAN (kanamycin)
#> For `carbapenems()` using columns IPM (imipenem) and MEM
#> (meropenem)
#> # A tibble: 35 × 7
#> bacteria GEN TOB AMK KAN IPM MEM
#> <chr> <sir> <sir> <sir> <sir> <sir> <sir>
@@ -225,8 +226,8 @@ wisca(example_isolates,
```
| Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin |
|:---|:---|:---|
| 70% (64.8-75.2%) | 93.6% (92-95.1%) | 89.9% (87.1-92.5%) |
|:------------------------|:-------------------------------------|:-------------------------------------|
| 70% (64.8-75.1%) | 93.6% (92.1-95%) | 89.9% (86.9-92.3%) |
WISCA supports stratification by any clinical variable, so you can
generate syndrome-specific or ward-specific coverage estimates:
@@ -240,10 +241,10 @@ wisca(example_isolates,
```
| Syndromic Group | Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin |
|:---|:---|:---|:---|
| Clinical | 74.6% (69.3-80.3%) | 93.6% (92.1-95%) | 90.4% (87-93.2%) |
| ICU | 56.9% (48.2-66.3%) | 86.7% (83.4-89.7%) | 82.9% (78.1-87.3%) |
| Outpatient | 57.3% (45.8-69.1%) | 76.6% (70.6-81.9%) | 67.9% (58-76.9%) |
|:----------------|:------------------------|:-------------------------------------|:-------------------------------------|
| Clinical | 74.7% (69-80.3%) | 93.6% (92-95.2%) | 90.4% (86.8-93.1%) |
| ICU | 56.9% (48.7-66%) | 86.8% (83.6-90%) | 82.8% (78.3-87.3%) |
| Outpatient | 57.2% (46-68.2%) | 76.5% (70.3-82.2%) | 67.7% (57.3-77.2%) |
**For AMR surveillance**, traditional antibiograms remain the right tool
for tracking resistance per species over time:
@@ -252,13 +253,14 @@ for tracking resistance per species over time:
antibiogram(example_isolates,
mo_transform = "gramstain",
antimicrobials = c("AMC", carbapenems(), "TZP"))
#> For `carbapenems()` using columns IPM (imipenem) and MEM (meropenem)
#> For `carbapenems()` using columns IPM (imipenem) and MEM
#> (meropenem)
```
| Pathogen | Amoxicillin/clavulanic acid | Imipenem | Meropenem | Piperacillin/tazobactam |
|:---|:---|:---|:---|:---|
| Gram-negative | 76% (73-79%,N=726) | 99% (98-100%,N=631) | 100% (99-100%,N=626) | 88% (85-91%,N=641) |
| Gram-positive | 76% (74-79%,N=1138) | 81% (75-85%,N=257) | 77% (70-82%,N=203) | 86% (82-89%,N=345) |
| Pathogen | Amoxicillin/clavulanic acid | Imipenem | Meropenem | Piperacillin/tazobactam |
|:--------------|:----------------------------|:--------------------|:---------------------|:------------------------|
| Gram-negative | 76% (73-79%,N=726) | 99% (98-100%,N=631) | 100% (99-100%,N=626) | 88% (85-91%,N=641) |
| Gram-positive | 76% (74-79%,N=1138) | 81% (75-85%,N=257) | 77% (70-82%,N=203) | 86% (82-89%,N=345) |
Combination antibiograms show the additional coverage gained by adding a
second agent, stratified by species:
@@ -269,10 +271,10 @@ antibiogram(example_isolates,
antimicrobials = c("TZP", "TZP+TOB", "TZP+GEN"))
```
| Pathogen | Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin |
|:---|:---|:---|:---|
| Gram-negative | 88% (85-91%,N=641) | 99% (97-99%,N=691) | 98% (97-99%,N=693) |
| Gram-positive | 86% (82-89%,N=345) | 98% (96-98%,N=1044) | 95% (93-97%,N=550) |
| Pathogen | Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin |
|:--------------|:------------------------|:-------------------------------------|:-------------------------------------|
| Gram-negative | 88% (85-91%,N=641) | 99% (97-99%,N=691) | 98% (97-99%,N=693) |
| Gram-positive | 86% (82-89%,N=345) | 98% (96-98%,N=1044) | 95% (93-97%,N=550) |
Like many other functions in this package, `antibiogram()` and `wisca()`
come with support for 28 languages that are often detected automatically
@@ -367,15 +369,16 @@ out <- example_isolates %>%
# calculate AMR using resistance(), over all aminoglycosides and polymyxins:
summarise(across(c(aminoglycosides(), polymyxins()),
resistance))
#> For `aminoglycosides()` using columns GEN (gentamicin), TOB (tobramycin), AMK (amikacin), and KAN
#> (kanamycin)
#> For `aminoglycosides()` using columns GEN (gentamicin), TOB
#> (tobramycin), AMK (amikacin), and KAN (kanamycin)
#> For `polymyxins()` using column COL (colistin)
#> Warning: There was 1 warning in `summarise()`.
#> In argument: `across(c(aminoglycosides(), polymyxins()), resistance)`.
#> In argument: `across(c(aminoglycosides(), polymyxins()),
#> resistance)`.
#> In group 3: `ward = "Outpatient"`.
#> Caused by warning:
#> ! Introducing NA: only 23 results available for KAN in group: ward = "Outpatient" (whilst `minimum =
#> 30`).
#> ! Introducing NA: only 23 results available for KAN in group:
#> ward = "Outpatient" (whilst `minimum = 30`).
out
#> # A tibble: 3 × 6
#> ward GEN TOB AMK KAN COL